Moderna: testing an experimental vaccine against norovirus

(CercleFinance.com) - Moderna has announced that the first participant has been dosed in a Phase 3 Nova 301 clinical trial in the USA, evaluating the efficacy, safety and immunogenicity of the investigational mRNA-1403 vaccine against norovirus (or winter vomiting disease).


The study aims to enroll 25,000 participants in several regions of the world, with a focus on adults aged 60 and over, who are most at risk of serious complications.

mRNA-1403 is an mRNA vaccine designed to prevent moderate to severe acute gastroenteritis caused by norovirus, a highly contagious virus responsible for many deaths each year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.